SRX Valuation, page-19

Given the 1st half results as well as the continued increase in dosage sales combined with the exchange rate benefit I would be amazed if full year sales are sub $180m. My original sales estimate (done 4 months ago) was $181.2. I am more confident now it will be closer to $190m. As for next year I think $320m is dreaming ($250m would be a magnificent result). However like you if revenue is only up 10% next year I will run naked down Bourke St in a stooped position pushing a cherry along the tram track!